Cyteir Therapeutics
Signal active
Organization
Contact Information
Overview
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.
About
Industries
Biotechnology, Pharmaceutical, Biopharma
Founded
2012
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Cyteir Therapeutics headquartered in United States, North America, operates in the Biotechnology, Pharmaceutical, Biopharma sector. The company focuses on Biotechnology and has secured $9.4B in funding across 60 round(s). With a team of 11-50 employees, Cyteir Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Cyteir Therapeutics, raised $5.5M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
5
Investors
1
Lead Investors
0
Total Funding Amount
$156.7M
Details
4
Cyteir Therapeutics has raised a total of $156.7M in funding over 4 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2018 | Early Stage Venture | 29.0M | ||
| 2019 | Early Stage Venture | 40.2M | ||
| 2021 | Late Stage Venture | 80.0M | ||
| 2015 | Early Stage Venture | 5.5M |
Investors
Cyteir Therapeutics is funded by 47 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| National Institutes of Health | - | FUNDING ROUND - National Institutes of Health | 2.0M |
| Maria Palmisano | - | FUNDING ROUND - Maria Palmisano | 5.5M |
| Cyteir Therapeutics | - | FUNDING ROUND - Cyteir Therapeutics | 5.5M |
| Celgene | - | FUNDING ROUND - Celgene | 5.5M |
Recent Activity
There is no recent news or activity for this profile.